[A16-69] Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 01.02.2017
Commission awarded on 01.11.2016 by the Federal Joint Committee (G-BA).
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A18-85||Cabozantinib (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A17-56||Cabozantinib (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A17-10||Cabozantinib (renal cell carcinoma) - Addendum to Commission A16-69||Commission completed|
|G14-07||Cabozantinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)||Commission completed|
|G21-20||Cabozantinib (thyroid carcinoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)||Commission completed|